Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 2/20 | 0.32 |
| ▸ | DRD3 | P35462 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | DRD1 | P21728 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13239162 | 0.79 | CXCR2 (0.34) | CXCR2NOTUMP2RX7CA1CA2 | |
| SCHEMBL13239157 | 0.76 | HDAC4 (0.36) | NOTUMP2RX7CA1CA2CA9 | |
| SCHEMBL13239154 | 0.75 | FYN (0.32) | CXCR2NOTUMFYNCA1CA2 | |
| SCHEMBL4234625 | 0.69 | NOTUM (0.41) | NOTUMDRD2DRD3DRD1DRD4 | |
| SCHEMBL259378 | 0.68 | DRD2 (0.48) | DRD2DRD3DRD1DRD4 | |
| SCHEMBL25372258 | 0.68 | DYRK1A (0.32) | — | |
| SCHEMBL4230517 | 0.66 | NOTUM (0.37) | NOTUM | |
| SCHEMBL3734117 | 0.64 | RAB9A (0.41) | CXCR2NOTUM | |
| SCHEMBL24915146 | 0.63 | — | — | |
| SCHEMBL4310987 | 0.61 | NOTUM (0.38) | CXCR2NOTUMP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074922-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. | 2025-03-06 | — | — | US | disclosed |
| US-11919915-B2 | Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations | AGIOS PHARMACEUTICALS, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-20230365592-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365592-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230339980-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339980-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339980-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| WO-2023164235-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023164235-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| US-20090258885-A1 | Diphenylmethane Derivatives as Inhibitors of Leukotriene Biosynthesis | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-20090197883-A1 | Diphenyl Substituted Cycloalkanes, Compositions Containing Such Compounds and Methods Of Use | MERCK SHARP & DOHME CORP. | 2009-08-06 | — | — | US | disclosed |
| EP-1858513-A4 | DIPHENYL SUBSTITUTED CYCLOALKANES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO INC (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-1954128-A2 | DIPHENYLMETHANE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | Merck & Co., Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1858513-A1 | DIPHENYL SUBSTITUTED CYCLOALKANES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | Merck & Co., Inc. (US) | 2007-11-28 | — | — | EP | disclosed |
| WO-2007056210-A2 | DIPHENYLMETHANE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK & CO., INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2006098912-A1 | DIPHENYL SUBSTITUTED CYCLOALKANES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11919915-B2 | Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations | PAH, KDM8, PHF8 | CXCR2 4066/4885NOTUM 1909/4885FYN 2255/4885 |
| US-20090258885-A1 | Diphenylmethane Derivatives as Inhibitors of Leukotriene Biosynthesis | LTC4S, LTA4H, ALOX5 | CXCR2 1765/4885NOTUM 203/4885FYN 3757/4885 |
| US-20230365592-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | CXCR2 4066/4885NOTUM 1909/4885FYN 2255/4885 |
| US-20250074922-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | CXCR2 3986/4885NOTUM 2494/4885FYN 1654/4885 |
| US-20230339980-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | CXCR2 4066/4885NOTUM 1909/4885FYN 2255/4885 |
| US-20090197883-A1 | Diphenyl Substituted Cycloalkanes, Compositions Containing Such Compounds and Methods Of Use | ALOX5, LTC4S, ALOX15B | CXCR2 567/4885NOTUM 179/4885FYN 2596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.